0001826667FALSE00018266672025-08-252025-08-250001826667us-gaap:CommonStockMember2025-08-252025-08-250001826667us-gaap:WarrantMember2025-08-252025-08-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2025
TRISALUS LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware | 001-39813 | 85-3009869 |
(State or other jurisdiction of incorporation or organization) | (Commission
File Number) | (I.R.S. Employer Identification No.) |
| | |
6272 W 91st Ave, Westminster, Colorado | | 80031 |
| (Address of principal executive office) | | (Zip Code) |
(888) 321-5212
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
| | | | | |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below): |
| o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: | | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.0001 par value | TLSI | Nasdaq Global Market |
| Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share | TLSIW | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
| | | | | | | | |
| Item 5.02 | | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August 25, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of TriSalus Life Sciences, Inc. (the “Company”), approved an increase in the annual compensation of Mr. David Patience, the Company’s Chief Financial Officer, from the he $450,000 annual base salary indicated in his Executive Employment Agreement dated May 27, 2025 to $550,000, effective immediately.
In addition, on August 28, 2025, the Compensation Committee approved the granting of stock options to purchase 249,899 shares of common stock to Mr. Patience, exercisable at $5.11 per share. The options vest upon the Company achieving or exceeding $75 million of revenue over any twelve (12) consecutive calendar month period period ending on or before December 31, 2027.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
Date: August 29, 2025 | TriSalus Life Sciences, Inc. |
| | | |
| | | |
| By: | /s/ Mary Szela |
| | Name: | Mary Szela |
| | Title: | Chief Executive Officer |
